These findings encouraged investigators to examine the hypothesis that CYP2D6 genotype status, and thus endoxifen concentrations, would affect clinical outcome in women treated with tamoxifen for their breast cancer. This evidence concerns the gene CYP2D6 and breast carcinoma.